HnRNPK is involved in stress-induced depression-like behavior via ERK-BDNF pathway in mice
Neurochemistry International · 2023
DOI: 10.1016/j.neuint.2023.105589 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurochemistry International, 2023. Verfasst von Lv-Ping Zhuang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Fujian Medical University Union Hospital, Fujian Key Laboratory of Molecular Neurology and Institute of Neuroscience, Fujian…. Hauptthemen laut MEDLINE: Depression, Major Depressive Disorder. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Natural Science Foundation of Fujian Province, National Natural Science Foundation of China.
Themen: Depression
Abstract (Originalsprache)
As a ubiquitous RNA-binding protein, heterogeneous nuclear ribonucleoprotein K (hnRNPK) interacts with numerous nucleic acids and proteins and is involved in various cellular functions. Available literature indicates that it can regulate dendritic spine density through the extracellular signal-regulating kinase (ERK) - brain-derived neurotrophic factor (BDNF) pathway, which is crucial to retain the synaptic plasticity in patients with major depressive disorder (MDD) and mouse depression models. However, ERK upstream regulatory kinase has not been fully elucidated. Furthermore, it remains unexplored whether hnRNPK may impact the depressive condition via the ERK pathway. The present study addressed this issue by integrating approaches of genetics, molecular biology, behavioral testing. We found that hnRNPK in the brain was mainly distributed in the hippocampal neurons; that it was significantly downregulated in mice that displayed stress-induced depression-like behaviors; and that the level of hnRNPK markedly decreased in MDD patients from the GEO database. Further in vivo and in vitro analyses revealed that the changes in the expressions of BDNF and PSD95 and in the phosphorylation of ERK (Thr202/Tyr204) paralleled the variation of hnRNPK levels in the ventral hippocampal neurons in mice with depression-like behaviors. Finally, esketamine treatment significantly increased the level of hnRNPK in mice. These findings evidence that hnRNPK involved in the pathogenesis of depression via the ERK-BDNF pathway, pinpointing hnRNPK as a potential therapeutic target in treating MDD patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Fujian Medical University Union Hospital, Fujian Key Laboratory of Molecular Neurology and Institute of Neuroscience, Fujian Medical University; Fuzhou, China.
- Department of Neurology, Fujian Medical University Union Hospital, Fujian Key Laboratory of Molecular Neurology and Institute of Neuroscience, Fujian Medical University; Fuzhou, China. Electronic address: drzj@163.com.
- Department of Neurology, Fujian Medical University Union Hospital, Fujian Key Laboratory of Molecular Neurology and Institute of Neuroscience, Fujian Medical University; Fuzhou, China. Electronic address: chenxc998@fjmu…
Förderung
- Natural Science Foundation of Fujian Province
- National Natural Science Foundation of China
Zitieren
APA
Zhuang, L. P., Gao, W. J., Fang, L. L., Zeng, G. R., Ye, Q. Y., Dai, X. M., Zhang, J., & Chen, X. C. (2023). HnRNPK is involved in stress-induced depression-like behavior via ERK-BDNF pathway in mice. Neurochemistry International. https://doi.org/10.1016/j.neuint.2023.105589
Vancouver
Zhuang LP, Gao WJ, Fang LL, Zeng GR, Ye QY, Dai XM, et al. HnRNPK is involved in stress-induced depression-like behavior via ERK-BDNF pathway in mice. Neurochemistry International. 2023. doi:10.1016/j.neuint.2023.105589
BibTeX
@article{Zhuang2023,
author = {Zhuang, Lv-Ping and Gao, Wei-Jie and Fang, Liu-Lv and Zeng, Gui-Rong and Ye, Qin-Yong and Dai, Xiao-Man and Zhang, Jing and Chen, Xiao-Chun},
title = {HnRNPK is involved in stress-induced depression-like behavior via ERK-BDNF pathway in mice},
journal = {Neurochemistry International},
year = {2023},
doi = {10.1016/j.neuint.2023.105589}
}
EUVIMED